Advances in the development of bacterial vector technology

Referance

• Kraehenbuhl JP, Neutra MR. Defense of mucosal surfaces: pathogenicity, immunity and vaccines. CUIT: Top. Mcrobiol Immunol 236, Springer-Verlag New York Inc., NY, USA (1998).
   Google Scholar
• Trach DD, Clemens JD, Ke NT, Thuy HT, Son ND, Canh ND. Field trial of a locally Produced, killed, oral cholera vaccine in Vietnam. Lancet 349, 231–235 (1997).
   PubMed Web of Science ®Google Scholar
• Trach DD, Cam PD, Ke NT etal. Investigations into the safety and immunogenicity of a killed oral cholera.
   Google Scholar
• Lockman S, Tappero JW, Kenyon TA, Rumisha D, Huebner RE, Binkin NJ. Tuberculin reactivity in a pediatric population with high BCG vaccination coverage. Lit. J. Tubed. LurgD& 3(1), 23–30 (1999).
   Google Scholar
• Germanier R, Furer E. Isolation and characterization of galE mutant Ty2la of Salmonella OR a candidate strain for a live oral typhoid vaccine. J. Infect. Dis. 141(553) (1975).
   Google Scholar
• Guleria I, Teitelbaum R, McAdam RA. Auxotrophic vaccines for tuberculosis. Nit. Med 2, 334–337(1996).
   Google Scholar
• Hohmann EL, Oletta CA, Killeen KP, Miller SI. phoP/phoQ-deletedSahnonella Oh/ (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J. Infect Dis. 173, 1408–1414 (1996).
   Google Scholar
• Sansonetti PJ, Arondel A, Fontaine H d'Hauteville, Bernardird ML. OmpB (osmo-regulation) and icsA (cell-to-cell spread) mutants of Shigella .11exned. vaccine candidates and probes to study the pathogenesis of shigellosis. Vaccine 9, 416–422 (1991).
   Google Scholar
• Killeen K, DiRita V. Live attenuated bacterial vaccines. In: New Vaccine Technologies.FIlisR (Ed.). Landes Bioscience, Georgetown, TX, USA (2000).
   Google Scholar
• Cancellieri V, Fara GM. Demonstration of specific IgA in human feces after immunization with live Ty2la Salmonella Ophi vaccine. Infect. Dis. 151 (3), 482–484 (1985).
   Google Scholar
• Viret J-F, Favre D, Wegmiiller B et al Mucosa' and systemic immune responses in humans after primary and booster immunizations with orally administered invasive and noninvasive live attenuated bacteria. Infect. Immun. 67(7), 3680–3685 (1999).
   PubMedGoogle Scholar
• Tagliabue A, Nencioni L, Caffarena A eta]. Cellular immunity against Salmonella typhi after live oral vaccine. Gun.Immunol 62(2), 242–247 (1985).
   Google Scholar
• Tacket CO, Sztein MB, Wasserman SS etal. Phase 2 clinical trial of attenuated Salmonella entedca serovar Typhi oral live vector vaccine CVD 908-htrA in US volunteers. Infect Immun. 68(3), 1196–1201 (2000).
   Google Scholar
• Hindle Z, Chatfield SN, Phillimore J. Characterization of Salmonella enter/ca derivatives harboring defined aroC and Salmonella pathogenicity island 2 type III secretion system (ssaV) mutations by immunization of healthy volunteers. Infect. Immun. 70(7), 3457–3467 (2002).
   Google Scholar
• Levine MM, Tacket CO, Sztein MB. Host—Salmonella interaction: human trials. M'cmbes Infect. 3, 271–1279 (2001).
   Google Scholar
• •Review of the status of Salmonella typhi vector and vaccine studies in humans.
   Google Scholar
• Formal SB, Baron LS, Kopecko DJ, Washington 0, Powell C, Life CA. Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the ga1E Salmonella Ophi Ty2la typhoid vaccine strain. Infect. Immun. 34(3), 746–750 (1981).
   Google Scholar
• Herrington DA, Verg LVD, Formal SB et al. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella Ophi—Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 8(4), 353–357 (1990).
   PubMedGoogle Scholar
• Gonzalez C, Hone D, Noriega FR eta]. Salmonella typhivaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparurd strain construction and safety and immunogenicity in humans. Infect. Dis. 13, 927–931 (1994).
   Google Scholar
• Tacket CO, Galen J, Sztein MB eta]. Safety and immune responses to attenuated Salmonella entericaserovar Typhi oral live vector vaccines expressing tetanus toxin fragment C. Gun. Immunol. 97(2), 146–153 (2000).
   Google Scholar
• Oral and rectal immunization of adult female volunteers with a recombinant attenuated Salmonella Ophi vaccine. Infect. Immun. 64(12), 5219–5224 (1996).
   PubMedGoogle Scholar
• Safety and immunogenicity in humans of an attenuated Salmonella Ophi vaccine vector strain expressing plasmid-encoded hepatitis B antigens stabilized by the Asd-balanced lethal vector system. Infect. Immun. 65(8), 3381–3385 (1997).
   PubMedGoogle Scholar
• Dipetrillo MD, Tibbetts T, Kleanthous H, Killeen K, Hohmann E. Safety and immunogenicity of phoP/phoQ-deleted Salmonella Ophi expressing Helicobacter pylori urease in adult volunteers. Vaccine 18, 449–459 (2000).
   Google Scholar
• Angelakopoulos H, Hohmann EL. Pilot study of phoP/phoQ-deleted Salmonella enter/ca serovar Typhimurium expressing Iklicobacter pylori urease in adult volunteers. Infect Immun. 68(4), 2135–2141 (2000). The first study to show the potential use of serovar Typhiminium as a vector organism in humans.
   Google Scholar
• Nakayama K, Kelly SM, Curtiss 3' R Construction of an Asd+ expression-cloning vector: stable maintenance and high-level expression of cloned genes in a Salmonella vaccine strain. Biotechnol 6,693–697 (1988).
   Google Scholar
• Tzschaschel BD, Guzman CA, Ilmmis KN, de Lorenzo V An Escherichia coil hemolysin transport system-based vector for the export of polypeptides: export of Shiga-like toxin IIeB subunit by Salmonella Ophimurium aroA.Biotechnol 14,765–769 (1996).
   Google Scholar
• Hess J, Dietrich G, Gentschev I, Miko D, Goebel W Kaufmann SHE. Protection against murine listeriosis by an attenuated recombinant Salmonella Ophimurium vaccine strain that secretes the naturally somatic antigen superoxide dismutase. Infect. Immun. 65(4), 1286–1292 (1997).
   Google Scholar
• Kwak Y-D, Yoo S-K, Kim EJ. Cell surface display of human immunodeficiency virus type 1 gp120 on Escherichia coli by using ice nucleation protein. Gun. Diagn. Lab. Immunol 6(4), 499–503 (1999).
   Google Scholar
• Jung H-C, Lebeault J-M, Pan J-G. Surface display of Zymomonas mobilislevan sucrase by using the ice-nucleation protein of Reudomonas syringae. Nat. Biotechnol 16, 576–580 (1998).
   Google Scholar
• Lee J-S, Shin K-S, Pan J-G, Kim C-J. Surface-displayed viral antigens on Salmonella carrier vaccine. Nat. Biotechnol. 18,645–648 (2000).
   Google Scholar
• Coulson NM, Fulop M, Titball RVV Bacillus antiwar's' protective antigen, expressed in Salmonella OphimtuiumSL 3261, affords protection against anthrax spore challenge. Vaccine 12(15), 1395–1401 (1994).
   Google Scholar
• Beyer W Griffin KE, Garmory H, Titball RVV Improvements in the development of live Sa/mone//a vectors for the delivery of vaccine candidates against B. anthracis. Board 39B. In: Abstracts of the Fotuth International Conference on Anthrax, Saint John's College, Andover, MD, USA (2001).
   Google Scholar
• Kim S, Kim H, Chai Y Cell surface display of Bacillusantkacis Protective Antigen on Escherichia coli by using ice nucleation protein. Roan] 36A. in Abstracts of the Fotuth International Conferrnce on Anthrax, Saint John's College, Andover, MD, USA (2001).
   Google Scholar
• Williamson ED, Eley SM, Griffin KF. A new improved sub-unit vaccine for plague: the basis of protection. FEMS Immunol Med. Mcrobiol. 12,223-230 (1995).
   Google Scholar
• Titball RVV, Howells AM, Oyston PCF, Williamson ED. Expression of the Yersinia pestis capsular antigen (Fl antigen) on the surface of an aroA mutant of Salmonella Ophimurium induces high levels of protection against plague. Infect. Immun. 65(5), 1926–1930 (1997).
   PubMedGoogle Scholar
• Leary SE, Griffin KF, Garmory HS, Williamson ED, Titball RVV Expression of an Fl/V fusion protein in attenuated Salmonella Ophimurium and protection of mice against plague. Mcrob. Pathog. 23 (3), 167–79 (1997).
   PubMedGoogle Scholar
• Pfeifer JD, Wick MJ, Roberts PL, Findley K, Normark SJ, Harding CV Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 361, 359–362 (1993).
   PubMed Web of Science ®Google Scholar
• Wick MJ, Harding CV, Twesten NJ, Normark SJ, Pfeifer JD. The phoP locus influences processing and presentaion of Salmonella Ophimurium antigens by acitvated marcrophages. Ma. Mcmbiol. 16,465–476 (1995).
   Google Scholar
• GOmez-Duarte OG, Pasetti ME, Santiago A, Sztein MB, Hoffman SL, Levine MM. Expression, extracellular secretion, and immunogenicity of the Plasmodium falciparumsporozoite surface protein 2 in Salmonella vaccine strains. Infect. Immun. 69(2), 1192–1198 (2001).
   Google Scholar
• Dietrich G, Gentschev I, Hess J, Ulmer JB, Kaufmann SH, Goebel W Delivery of DNA vaccines by attenuated intracellular bacteria. Immunol Today 20(6), 251–253 (1999).
   PubMedGoogle Scholar
• Darji A, Guzman CA, Gerstel B etal. Oral somatic transgene vaccination using attenuated S. Ophimurium. Cell 91(6), 765–775 (1997).
   Google Scholar
• Paglia P, Medina E, Arioli I, Guzman CA, Colombo MP. Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella Ophimurium, results in protective immunity against a murine fibrosarcoma. Blood 92(9), 3172–3176 (1998).
   PubMedGoogle Scholar
• Shata MT, Reitz MS Jr, DeVico AL, Lewis GK, Hone DM. Mucosa' and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector. Vaccine 20(3–4), 623–629 (2001).
   Google Scholar
• Jain KK. Use of bacteria as anticancer agents. Expert Opin. Biol. Therap. 1(2), 291–300 (2001).
   Google Scholar
• Saltzman DA, Katsanis E, Heise CP eta]. Antitumor mechanisms of attenuated Salmonella Ophimurium containing the gene for human interleukin-2: a novel antitumor agent? J. Pediatr Slug 32 (2), 301–306 (1997).
   Google Scholar
• Low KB, Ittensohn M, Le T eta]. Lipid A mutant Salmonella with suppressed virulence and TNF-a induction retain tumor-targeting in vivo. Nat. Biotechnol 17, 37–41 (1999).
   Google Scholar
• Zheng LM, Luo X, Feng M eta] Tumor amplified protein expression therapy: Salmonella as a tumor-selective protein delivery vector. Oncol Res. 12,127–135 (2000).
   PubMedGoogle Scholar
• Hassan JO, Curtiss III R. Control of colonization by virulent Salmonella Ophimurium by oral immunization of chickens with avirulent Acya Acrp S. Ophimurium. Res. Mcrobiol 141,839–850 (1990).
   PubMedGoogle Scholar
• Hassan JO, Curtiss III R. Development and evaluation of an experimental vaccination program using live avirulent Salmonella Ophimuriumto protect immunized chickens against challenge with homologous and heterologous Salmonella serotypes. Infect. Immun. 62 (12), 5519–5527 (1994).
   PubMedGoogle Scholar
• Hassan JO, Curtiss III R Effect of vaccination of hens with an avirulent Salmonella Ophimurium on immunity of progeny challenged with wild-type Salmonella strains. J. Bacteria 64,938–944 (1996).
   Google Scholar
• Coster TS, Hoge CVV, VanDeVerg LL eta]. Vaccination against shigellosis with attenuated Shigella Ilexneri2a strain SC602. Infect. hnmun. 67, 3437–3443 (1999).
   Google Scholar
• Kotloff KL, Noriega F, Losonsky GA et al Safety, immunogneicity, and transmissibility in humans of CVD 1203, a live oral Shigella Ilexneri 2a vaccine candidate attenuated by deletions in aroA and virG. Infect. Immun 64, 4542–4549 (1996).
   Google Scholar
• Kotloff KL, Taylor DN, Sztein MB eta]. Phase I evaluation of AvirG Shigella sonnei live, attenuated oral vaccine strain WRSS1 in healthy adults. Infect. Immun. 70(4), 2016–2021 (2002).
   Google Scholar
• Kotloff KL, Noriega FR, Samandari T et al Shigella Ilexneri 2a strain CVD 1207, with specific deletions in virG, sen, set, and guaBA, is highly attenuated in humans. Infect. Immun. 68, 1034–1039 (2000).
   Google Scholar
• Barzu S, Arondel J, Guillot S, Sansonetti PJ, Phalipon A. Immunogenicity of IpaC-hybrid proteins expressed in the Shigella Ilexneri 2a vaccine candidate 5C602. Infect. Immun. 66, 77–82 (1998).
   Google Scholar
• Noriega FR, Losonsky G, Wang JY, Formal SB, Levine MM. Further characterization of AaroA and AvirG Shigella Ilexneri 2a strain CVD 1203 as a mucosal Shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escberichia roll Infect. Immun. 64, 23–27 (1996).
   Google Scholar
• Sizemore DR, Branstrom A, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 270, 299–302 (1995).
   Google Scholar
• • Attenuated Shigella was the first bacterial vector used to deliver plasmid DNA.
   Google Scholar
• Sizemore DR, Branstrom A, Sadoff JC. Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization. Vaccine 15, 804–807 (1997).
   Google Scholar
• Fennelly GJ, Khan SA, Abadi MA, Wild TF, Bloom BR Mucosal DNA vaccine immunization against measles with a highly attenuated Shigella Ilexneri vector. J. Immunol 162, 1603–1610 (1999).
   PubMed Web of Science ®Google Scholar
• Kaufmann SH. Immunity against intracellular bacteria. In: Annual Reviews of Immunology 11, 129–163 (1993).
   PubMed Web of Science ®Google Scholar
• Shen H, Slifka MK, Matloubian M, Jensen ER, Ahmed R, Miller JR Recombinant Listeria monocytogenes as a live vaccine vehicle for the induction of protective anti-viral cell-mediated immunity. Proc. Nat! Arad Li. USA 92, 3987–3991 (1995).
   PubMed Web of Science ®Google Scholar
• Thompson RJ, Bouwer HGA, Portnoy DA, Frankel FR. Pathogenicity and immunogenicity of a Listeria monocytogenes strain that requires D-alanine for growth. Infect. Immun. 66(8), 3552–3561 (1998).
   PubMedGoogle Scholar
• Angelakopoulos H, Loock K, Sisul DM, Jensen ER, Miller JR, Hohmann EL. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect. Immun. 70(7), 3592–3601 (2002).
   PubMedGoogle Scholar
• Goossens PL, Milon G, Cossart P, Saron ME. Attenuated Listeria monocytogenes as a live vector for induction of CD8+ T cells in vivo: a study with the nucleoprotein of the lymphocytic choriomeningitis virus. hit. Immunol 7, 797–805 (1995).
   Google Scholar
• Shen H, Miller JF, Fan X, Kolwyck D, Ahmed T, Harty JT. Compartmentalization of bacterial antigens: differential effects on priming of CD8 T cells and protective immunity. Cell 92, 535–545 (1998).
   PubMedGoogle Scholar
• Paterson Y, Ikonomidis G. Recombinant Listeria monocytogenes cancer vaccines. CUIT: Opin. Immunol 8.664–669 (1996).
   Web of Science ®Google Scholar
• Pan ZK, Ikonomidis G, Lazenby A, Pardon D, Paterson Y. A recombinant Listeria monocytogenes vaccine expressing a model tumor antigen protects mice against lethal tumor challenge and causes regression of established tumors. Nat. Med 1, 471–477 (1995).
   Google Scholar
• Dietrich G, Bubert A, Gentschev 1 etal. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attentuated suicide Listeria monocytogenes. Nat. Biotechno1.16, 181–185 (1998).
   Google Scholar
• Stover CK, de la Cruz VF, Fuerst TR etal. New use of BCG for recombinant vaccines. Nature 351, 456–460 (1991).
   PubMed Web of Science ®Google Scholar
• Lagranderie M, Winter N, Balazuc AM, Gicquel B, Gheorghiu M. A cocktail of Mycobacterium bovis BCG recombinants expressing the SW Nef, Env, Gag antigens induces antibody and cytotoxic responses in mice vaccinated by different mucosal routes. AIDS Res. Hum. Renvviruses 14, 1625–1633 (1998).
   Google Scholar
• Stover CK, Bansal GP, Hanson MS et al Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine. J. Exp. Med 178, 197–209 (1993).
   PubMed Web of Science ®Google Scholar
• Edelman R, Palmer K, Russ KG eta] Safety and immunogenicity of recombinant Bacille Calmette-Guerin (rBCG) expressing Borielia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine 17, 904–914 (1998).
   Google Scholar
• Lussow AIR, Del GG, Renia L et a/. Use of tuberculin purified protein derivative-Asn—Ala—Asn—Pro conjugate in bacillus Calmette-Guerin primed mice overcomes H-2 restriction of the antibody response and avoids the need for adjuvants. Proc. Nat/Arad Li USA 87, 2960–2964 (1990).
   Google Scholar
• Matsumoto S, Yukitake H, Kanbara H, Yamada T. Recombinant 114,cobacterium bovis bacillus Calmette-Guerin secreting merosoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon-y and parasite-specific antibodies. J. Exp. Med 188(5), 845–854 (1998).
   Google Scholar
• Hess J, Miko D, Catic A, Lehmensiek V, Russell DG, Kaufmann SHE. Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes. Proc. Natl Acad. Li. USA 95, 5299–5304 (1998).
   PubMed Web of Science ®Google Scholar
• Kaufmann SHE. Fundamental Immunology Paul WE (Ed.). Raven Press, New York, NY, USA (1997).
   Google Scholar
• Pearson GD, Woods A, Chiang SL, Mekalanos JJ. CTX genetic element encodes a site-specific recombination system and an intestinal colonization factor. Pim Nat/Arad Li USA 90, 3750–3754 (1993).
   PubMedGoogle Scholar
• Levine MM, Kaper JB, Herrington D eta] Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR Lancet 2, 467–470 (1988).
   Google Scholar
• Taylor DN, Killeen KP, Hack DC eta] Development of a live, oral, attenuated vaccine against El Tor cholera. J. Infect Dis. 170, 1518–1523 (1994).
   PubMed Web of Science ®Google Scholar
• Butterton JR, Beattie DT Gardel CL etal. Heterologous antigen expression in Vibrio choleraevector strains. 63, 2689–2696 (1995).
   Google Scholar
• Butterton JR, Ryan ET, Acheson DVVK, Calderwood SB. Coexpression of the B subunit of Shiga toxin 1 and EaeA from enterohemorrhagic Escberichia robin Vibrio cbolerae vaccine strains. Infect Immun. 65, 2127–2135 (1997).
   PubMedGoogle Scholar
• Ryan ET, Butterton JR, Smith RN, Carroll PA, Crean TI, Calderwood SB. Protective immunity against Clostridium difficile toxin A induced by oral immunization with a live, attenuated Vibrio cbolerae vector strain. Infect. Immun. 65, 2941–2949 (1997).
   PubMed Web of Science ®Google Scholar
• Acheson DVVK, Levine MM, Kaper JB, Keusch GT. Protective immunity to Shiga-like toxin I following oral immunization with Ship-like toxin I B-subunit-producing Vibrio cbolerae CVD 103-HgR. Infect. Immun. 64,355-357 (1996).
   Google Scholar
• Favre D, Cryz SJ Jr,Viret J-F. Development of Shigella sonnei live oral vaccines based on defined rfbinaba deletion mutants of Vibrio cbolerae expressing the Shigella serotype C 0 polysaccharice. Infect. Immun. 64(2), 576–584 (1996).
   Google Scholar
• Hess J, Gentschev I, Miko D etal Superior efficacy of secreted over somatic antigen display in recombinant Satmonetta vaccine induced protection against listeriosis. Pim A&tlAcad Sci USA 93,1458–1463 (1996).
   PubMed Web of Science ®Google Scholar
• Connell TD, Metzger DJ, Wang M, Jobling MC, Holmes RK. Initial studies of the structural signal for extracellular transport of cholera toxin and other proteins recognized by Vibrio cbolerae. Infect. Immun. 63,4091–4098 (1995).
   Google Scholar
• Backstrom M, Lebens M, Schodel F, Holmgren J. Insertion of a HIV-1-neutralizing epitope in a surface-exposed internal region of the cholera toxin B-subunit. Gene 149,211–217 (1994).
   PubMedGoogle Scholar
• Holmgren J, Czerkinsky C, Lycke N, Svennerholm AM. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier and adjuvant. Am. J. 7i-op. Med Hygiene 50(Suppl.) 42–54 (1994).
   Google Scholar
• Ryan ET, Butterton JR, Zhang T, Baker MA, Stanley SL, Calderwood SB. Oral immunization with attenuated vaccine strains of Vibrio cbolerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal anti-amebic and anti- V cbolerae antibody responses in mice. Infect. Immun. 65,3118–3125 (1997).
   PubMed Web of Science ®Google Scholar
• Ryan ET, Butterton JR, Smith RN, Carroll PA, Crean TI, Calderwood SB. Protective immunity against Clostridium düncitetoxin A induced by oral immunization with a live, attenuated Vibrio cboleraevector strain. Infect. Immun. 65,2491–2449 (1997).
   PubMedGoogle Scholar
• Ryan ET, Crean TI, Kochi SK etal Development of a AglnA balanced lethal plasmid system for expression of heterologous antigens by attenuated vaccine vector strains of Vibrio cbolerae. Infect. Immun. 68,221–226 (2000).
   PubMed Web of Science ®Google Scholar
• Attridge SR, Davies R J ARrooy T. Oral delivery of foreign antigens by attenuated Salmonella: consequences of prior exposure to the vector strain. Vaccine15,155–162 (1997).
   PubMed Web of Science ®Google Scholar
• Bao JX, Qements JD. Prior immunologic experience potentiates the subsequent antibody response when Salmonella strains are used as vaccine carriers. IllfeCt. 59,3841–3845 (1991).
   Google Scholar
• Whittle BL, Verma NK. The immune immunological experience. Vaccine 15, 1737–1740 (1997).
   PubMed Web of Science ®Google Scholar
• Brown TA. Effect of pre-existing immunity to Salmonella on the immune response to recombinant Salmonella entericaserovar Typhimurium expressing a Porpbyromonas gingiva& hemagglutinin. Infect. Immun. 95Roberts M, Bacon A, Li J, Chatfield S.
   Google Scholar
• Prior immunity to homologous, and heterologous Salmonella serotypes suppresses local systemic anti-fragment C antibody responses and protection from tetanus toxin in mice immunized with 104.
   Google Scholar
• Forrest BD. Impairment of immunogenicity of Salmonella OphiTy2la due to pre-existing cross-reacting intestinal antibodies. In: Advances in Mucosal Immunology Mestecky J, Russell MW (Eds). Plenum Press: New York, NY, USA (1995).
   Google Scholar
• Kollaritsch H, Cryz SJ Jr, Lang AB, Herzog C, Que JU, Wiedermann G. Local and systemic immune responses to combined Vibrio cholerae CVD 103-HgR and Salmonella Obi Ty2la live oral vaccines after primary immunization and reimmunization. Vaccine 18(26), 3031–3039 (2000).
   Google Scholar
• Kollaritsch H, Furer E, Herzog C, Wiedermann G, Que JU, Cryz SJ Jr. Randomized, double-blind placebo-controlled trial to evaluate the safety and immunogenicity of combined Salmonella Ty21a and Vibrio cboleraeCVD 103- HgR live oral vaccines. Infect. Immun. 64(4), 1454–1457 (1996).
   Google Scholar
• Coster TS, Killeen DP, Waldor MK etal Safety, immunogenicity, and efficacy of live attenuated Vibrio cbolerae 0139 vaccine prototype. Lancet345 (8955), 949–952 (1995).
   Google Scholar
• Roland K, Curtiss III R, Sizemore D. Construction and evaluation of a Acya Acrp Salmonella Ophimurium strain expressing avian pathogenic Escherichia roll 078 LPS as a vaccine to prevent airsacculitis in chickens. Avian Dis. 43,429–441 (1999).
   PubMed Web of Science ®Google Scholar
• Pasetti MF, Pickett TE, Levine MM, Sztein MB. A comparison of immunogenicity and in vivo distribution of Salmonella entericaserovar typhi and typhimurium live vector vaccines delivered by mucosal routes in the murine model. Vaccine 18,3208–3213 (2000).
   PubMedGoogle Scholar
• Butterton JR, Ryan ET, Shahin RA, Calderwood SB. Development of a germfree mouse model of Vibrio cholerae infection. Infect. Immun. 64(10), 4373–4377(1996).
   PubMedGoogle Scholar
• Zegers ND, Kluter E, van der Strap H etal. Expression of the protective antigen of Bacillus anthracis by Lactobacillus caset. towards the development of an oral vaccine against anthrax. J. Appl. IVlicrobiol. 87, 309–314 (1999).
   Google Scholar
• Merlaglini D, Pozzi G, King TP, Fischetti VA. Mucosal and systemic immune responses to a recombinant protein expressed on the surface of the oral commensal bacterium Streptococcus gordonii after oral colonization. Proc. Natl Acad. Sci. USA 92,6868–6872 (1995).
   PubMedGoogle Scholar
• Hess J, Dietrich G, Gentschev I, Miko D, Goebel W SHE Kaufmann. Protection against murine listeriosis by an attenuated recombinant Salmonella Ophimurium vaccine strain that secretes the naturallly somatic antigen superoxide dismutase. Infect. Immun. 65(4), 1286–1292 (1997).
   Google Scholar
• Byrd CM, Bolken TC, Jones KF eta] Biological consequences of antigen and cytokine co-expression by recombinant Streptococcus garlonii vaccine vectors. Vaccine 20(17-18), 2197–2205 (2002).
   PubMedGoogle Scholar
• Xiang R., Lode HN, Chao TH et al. An autologous oral DNA vaccine protects against murine melanoma. Proc. Natl Acad Sci. USA 97(10), 5492–5497 (2000).
   Google Scholar